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Management of low grade glioma (LGG), particularly with
regards to the role of surgery, is not clear to most
clinicians. LGG constitutes only a small subset of gliomas,
the most common type of primary brain tumors. Primary
brain tumors, in turn, make up two-thirds of all brain
tumors, and half of all primary brain tumors are gliomas
(Figure 1).1 As the name implies, gliomas originate from
glial cells, primarily astrocytes and oligodendrocytes. They
are c lassif ied, based on thei r cel l of  origin, into
astrocytomas and oligodendrogliomas. Histopathological
features determine the degree of biological malignancy,
which is not divided into discrete categories but actually
forms a biological continuum (Table 1). 
It is not uncommon to find gliomas that seem to be a
combination of astrocytoma and oligodendroglioma cells -
these are called oligoastrocytomas. Those astrocytomas
that show all the features of malignancy, particularly
necrosis, are termed glioblastoma multiforme (GBM),
which is the most malignant variant of astrocytoma.
Oligodendrogliomas, as they undergo anaplastic de-
differentiation, acquire histopathologic features and
clinical behavior indistinguishable from GBM.  
LOW GRADE GLIOMA COMPRISES ASTROCYTOMA AND
OLIGODENDROGLIOMA LACKING MALIGNANT
HISTOLOGICAL FEATURES
According to the World Health Organization (WHO)
classification, astrocytomas range from grades I through
IV,2 with grade IV corresponding to GBM whereas grade I
corresponds to a subset of biologically benign tumors of
which pilocytic astrocytoma is the most common. This
latter variant is considered by some experts to be a
different pathological entity altogether, even though it
seems to represent the benign end of the astrocytoma
histopathology spectrum. Prognosis in grade I astrocytoma
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Figure 1. Incidence of primary brain tumors versus secondary brain tumors (metastasis) is shown in (a) along with the fraction of primary brain
tumors that consists of glioma; (b) shows further distribution of the types of glioma. (Modified from Osborne1) 
Figure 1(a) Figure 1(b)




• Cellularity and cellular pleomorphism
TABLE 1
Histopathological Features of Glioma
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is excellent and gross total resection results in cure. Grade
I astrocytomas also show certain unique histopathologic
features and display distinct imaging findings, such as
intense contrast enhancement, hence the reluctance to
group the together with other astrocytomas. Another
widely used classification is the St. Anne/Mayo system.
Grades in this classification do not correlate with the WHO
classification and can be a source of some confusion.
Table 2 compares these two classification systems.
Anaplastic astrocytoma, anaplastic oligodendroglioma,
and GBM are grouped together as high grade gliomas
(HGG), whereas benign variants of astrocytoma and
oligodendroglioma are grouped together as low grade
gliomas (LGG). For clinicopathologic purposes, only WHO
grade II astrocytoma and WHO grade II oligodendroglioma
(the lowest grade,  as there is no grade I
oligodendroglioma in the WHO classification) comprise
LGG. WHO grade I astrocytomas (such as pilocytic
astrocytoma), although technically a part of LGG, have a
much better prognosis; they are thus clinically distinct,
and not discussed in the prognosis and treatment of LGG.
Other  pr imary bra in tumors such as p leomorphic
xanthoastrocytoma (an astrocytoma var iant) and
neurocytoma are classified as WHO grade II, and other
entities such as dysembryoblastic neuro-epithelial tumors
and gangliogliomas are classified as grade I along with
pilocytic astrocytoma.
MORBIDITY IN LGG RESULTS FROM MALIGNANT
PROGRESSION
LGG in general have a much better prognosis than HGG.
Table 3 compares overall survival in LGG versus HGG
patients. Oligodendrogliomas have a better prognosis than
astrocytomas. In gliomas with cells derived from both glial
lineages, the overall behavior of the tumor resembles
oligodendroglioma.
Morbidity from LGG results from their invasive nature and,
more importantly, from de-differentiation into higher grade
gliomas over time. The propensity for LGG to transform
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Figure 2. Progression of genetic changes that lead to malignant
progression from a normal astrocyte to GBM. These include
genetic and epigenetic changes and vary widely. This is a general
pattern and progression may not always follow precisely the
sequence presented. (Modified from Kaye and Walker4)
St. Anne/Mayo Classification WHO Classification Low or High Grade
Astrocytoma grade 1 Pilocytic Astrocytoma (Grade I )
Astrocytoma grade 2 Astrocytoma (WHO Grade II )
Astrocytoma grade 3 Anaplastic Astrocytoma (WHO Grade III )
Astrocytoma grade 4 Glioblastoma Multiforme
TABLE 2
A comparison of astrocytoma classification
} Low grade gliomas (LGG)
High grade gliomas (HGG)}
into HGG seems to correlate with its vascular density and
expression of vascular endothelial growth factor.3 I t
appears that a lthough most  GBMs arise de-novo,
approximate ly 5% of  GBM are secondary with
histopathological evidence of a precursor low grade or
anaplastic astrocytoma. Many GBMs actually result from
accumulation of progressive genetic mutations that occur
in lower grade gliomas (Figure 2).4,5
SEIZURES ARE THE MOST COMMON PRESENTATION
LGG usually present with seizures. Headaches and slowly
progressive neurologic deficits such as paresis or sensory
symptoms may also be the presenting symptoms.
Increased intracranial pressure, either because of mass
effect or from hydrocephalus due to obstruction of
cerebrospinal fluid flow, is an uncommon presentation for
LGG. Seizures associated with LGG can be focal, complex
partial, or generalized. As a rule, all new onset seizures
(particularly adult onset seizures) should be investigated
by brain imaging; the study of choice is MRI with and
without contrast. An initial CT scan offers no additional
advantage.
MRI REVEALS LGG AS A LOCALIZED,
NON-ENHANCING MASS 
The characteristic MRI appearance of LGG is a space-
occupying lesion that is hyperintense on T2-weighted and
FLAIR images but hypo-intense on T1-weighted images
(Figure 3). A consistent feature of LGG is the lack of
contrast enhancement on MRI. HGG, on the other hand,
usually enhance markedly with contrast, typically in an
irregular ring-like pattern (Figure 3). LGG usually occur
supra-tentorially, with the most common site being frontal
and then temporal lobes. Rarely, LGG are found in the
cerebellum, brainstem, or spinal cord. It should be noted,
though, that not all LGG present as non-enhancing lesions
on MRI, and not all HGG enhance. The MRI characteristics
can occasionally be confusing. In cases where a non-
enhancing lesion is assumed to be an LGG and the
patient and the neurosurgeon decide to follow the patient
without any biopsy, any new enhancement or any change
in the size of the lesion suggests progression to HGG.
Malignant progression in these cases should be assumed
unless proven otherwise.
AGE, SIZE AND NEUROLOGIC DEFICIT ARE IMPORTANT
PROGNOSTIC INDICATORS
An understanding of factors predicting survival in LGG
comes from a prospective study conducted by the EORTC
(European Organization for Research and Treatment of
Cancer). Only a few factors were found to be associated
with good outcome.6 Of these, age at initial presentation
(less than 40 years), size of tumor (less than 6 cm),
extent of tumor across the midline (nil), histological type
(oligodendroglioma or oligoastrocytoma), and extent of
neurologic deficit (none) were most signif icant in
predicting survival (Table 4). These indicators were noted
to have an additive effect.
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Figure 3. MR image of a typical LGG lesion (a-c) and a typical
HGG lesion (d). The tumor is hypointense and non-enhancing on a
T1 weighted contrast-enhanced image (a), and shows
hyperintensity on T2 weighted (b) and FLAIR (c) images. In this
lesion, FLAIR imaging brings out a cystic portion in the center of
the LGG mass which is not evident on T1 weighted or T2 weighted
images; (d) shows a ring-enhancing mass which is extending
subependymally; this is a biopsy-proven GBM.
Glioblastoma 1-1.5 years
Anaplastic Astrocytoma 2-3 years
Anaplastic Oligodendroglioma 3-7 years
Low Grade Astrocytoma 6-7 years
Low Grade Oligodendroglioma 8-12 years
TABLE 3
Median Survival in Glioma Patients
INITIAL MANAGEMENT
Since patients usually present with seizure, the first step
is to start anti-epileptic medication. Valproic acid,
phenytoin, and carbamzepine are reasonable choices. In
recalcitrant cases, toparimate, or polytherapy with more
than one anti-epileptic medication, can be considered.
The role of corticosteroid therapy such as dexamethasone
is not clearly defined in LGG. Typically, these lesions are
not associated with any substantial vasogenic edema.
Anecdotal experience suggest that patients who present
with headache and have a large lesion on MRI may
experience relief from headaches with dexamethasone,
which has a dose-related effect on vasogenic edema. Use
of corticosteroids should always be combined with gastric
ulcer/gastritis prophylaxis. Proton pump inhibitors (PPI)
seem to work better in these situations than H2 histamine
receptor blockers. Antacids or combination of PPI and H2-
blockers do not have any additive effect. The use of
steroids is limited by the risk of long-term side-effects
resulting from prolonged use.
BETTER SURVIVAL IS SEEN WITH >90% TUMOR
RESECTION
Surgical management of LGG cannot yet be encapsulated
in the form of a guideline. It is still considered optional by
many neurosurgeons. Extent of resection ranges from a
simple biopsy to almost complete removal of tumor
tissue. It is impossible to claim total tumor resection as
these tumors are typically very invasive and the margins
cannot be definitively ascertained due to lack of a defining
capsule. In non-excisional biopsy, only a small part of the
tumor (typically just 1 or 2 square cubic millimeters) is
removed through a burr hole with or without the help of
stereotactic navigation technology. Tumor may be
described as gross total resection, near total resection,
subtotal resection, and partial resection (Table 5). Many a
time more than 90% resection, which technically is a near
total resection, is called gross total resection.  
Confusion about the role of surgery in LGG stems from a
lack of adequate randomized controlled trials. Several
studies have suggested that surgery plays a central role in
the treatment of LGG (Table 6).7 - 1 4 The most extensive
prospective data comes from an EORTC study,1 5 w h i c h
was randomized for the efficacy of two different doses of
radiation. Patients were enrolled after surgery and, based
on the type of surgery, were stratified into three groups -
biopsy or less than 50% resection; 50% or more but less
than 90% resection; and 90% or greater resection. Extent
of resection was est imated by the operating
neurosurgeon; logistical complexity precluded precise
volumetric assessment through imaging. Despite this
caveat, the data show an impressive trend toward higher
surv ival with greater resection. Both survival and
progression-free survival at 5 years after resection are
higher by 40% in those undergoing gross total (or near
total) resection, compared with those who underwent
biopsy or less than 50% resection (Figure 4).
CLINICAL REASONING FAVORS SURGICAL RESECTION
Apart from increased life expectancy, several other
objectives support surgical resection of LGG (Table 7),
including relief of neurologic deficit, control of medically
intractable seizures, or reduction in raised intracranial
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Biopsy (non-excisional) Few mm of tissue
Partial resection < 50% of tumor mass
Subtotal resection 50%-90% of tumor mass
Near total resection >90% of tumor mass
Gross total resection Complete resection of tumor 
visible by naked eye or a 
surgical microscope
TABLE 5
Definition of Extent of Intervention during 
Surgery of Glioma
In Favor of Not in Favor of
• Histopathological diagnosis • Rsik of neurological deficits
• Alleviating the symptoms • Lack of any randomized
due to mass effect controlled trial proving the
• Reducing the chance of
malignant progression
• Reducing the number of




Debate about Surgery in Low Grade Glioma
• Age less than 40 years
• Size of tumor less than 6 cm
• Tumor not crossing the midline
• Oligodendroglioma or oligoastrocytoma on hisotology
• Absence of any neurologic deficit
After Pignatti et al6
TABLE 4
Positive Prognostic Indicators in Adult Patients with
Cerebral LGG
efficacy of surgery for
LGG
pressure. Contrast enhancement in a mass lesion
otherwise consistent with LGG is suggestive of malignant
transformation; similarly a presumed or biopsy-proven LGG
that demonstrates a new pat tern of cont rast-
enhancement or an increase in size also needs attention.
These cases should be considered for surg ica l
intervention. 
Arguments against surgery mainly focus on two points: (i)
lack of any randomized controlled trial establishing the
benefit of surgery; and (ii) risk of neurological deficits in
patients who are intact or have minimal deficits pre-
operatively. Although more evidence has come forth
supporting the role of surgery in the management of LGG,
the debate continues. Several points favor surgical
intervention (Table 7). An imaging diagnosis of LGG
requires histological confirmation; rarely, even a GBM can
mimic LGG as a non-enhancing mass on MRI. For lesions
causing mass effect, debulking the tumor is desirable. The
pool of cells constituting the LGG eventually gives rise to a
focus that transforms into HGG; therefore, decreasing the
cellular population of the LGG will decrease the chance of
a focus turning malignant. Theoretically, resection of more
than 90% of tumor (near total or gross total resection)
should decrease the chance of malignant progression to
one-tenth. Decreasing the number of proliferating cells by
debulking the tumor should also decrease the growth rate
and decrease the number of cells that are resistant to
radiation therapy or chemotherapy. 
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Figure 4. Data as presented in a graph by Karim et al15 highlighting the beneficial effect of >90% tumor resection
on progression-free survival or overall survival in patients with LGG.  
Figure 5. MRI of LGG present in the dominant hemisphere of a
right-handed male, mainly in the insular and sub-insular region.
The lesion does not enhance on contrast: (a) T1 weighted contrast-
enhanced axial image; (b) T2 weighted axial image; (c) FLAIR
coronal image; and (d) T1 weighted contrast-enhanced sagittal
image.
Neurosurgical imperatives in LGG are offset by safety
concerns. Surgical manipulation of lesions in or near
eloquent or sensitive areas of the brain may lead to
profound postoperative deficits. These cases are better
off  with observat ion a lone or, at most , a b iopsy
(stereotactic or otherwise) with serial follow-up imaging
studies. Advanced age or other medical conditions,
particularly cardiopulmonary feebleness, are other
relative contraindications for surgical resection of LGG
(Table 7). 
In s ituations where a non-enhancing LGG mass is
located in an eloquent or deep region of the brain,
observation alone is the most judicious option (Figure 5).
If the LGG is located in eloquent cortex and displays an
increase in s i ze over  time,  appearance of  new
enhancement, change in the pattern of enhancement, or
worsening neurological symptoms, careful surgical
excision is necessary. A computerized neuro-navigation
system as well as intra-operative cortical mapping while
keeping the patient awake should be used to minimize
the chance of post-operative deficits (Figure 6). The
natural tendency of patients and families is to shy away
from surgical intervention. At a minimum, however,
biopsy of the mass lesion should be done, particularly
where features suggest a higher grade (Figure 7). 
A l though the options of  b iopsy, re sec tion, and
observation are ava ilable whether the lesion is in
eloquent cortex or not, aggressive management should
be pursued for masses in non-eloquent areas that harbor
features of higher grade tumor. Seria l imaging is
necessary in all cases, and should be continued after
resect ion to monitor  for recur rence.  There is no
consensus about decision making in the treatment of
LGG, but the flow diagram shown in Figure 8 conforms to
generally accepted practice.
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Figure 6. Craniotomy for a grade II oligodendroglioma in the right motor cortex. Surgery is being done with the assistance of
cortical mapping with the patient awake, along with assistance provided by neuro-navigation. Inset shows a close-up of the
motor cortex with temporary labels placed on the cortex to delineate the motor area.
TEMOZOLAMIDE IS THE MOST APPROPRIATE
CHEMOTHERAPY BUT OPTIMAL TIMING IS UNKNOWN
Although the efficacy of chemotherapy in the treatment of
LGG is unproven, several choices are available for use in
both  the pediatr ic and adult  populations.1 6 - 1 9
Temozolamide, an alkylating agent, has been used more
recently as the drug of  choice. Ni trosurea-based
chemotherapy is an a lternat ive. The timing of
chemortherapy is not established. Chemotherapy soon
after surgical resection is a valid option. Alternatively,
chemotherapy can be held until there is evidence of
progression on follow-up scans, with or without resection.
For pediatric patients, the chemotherapy of choice is a
combination of etoposide, cisplatin, procarbazine,
vincristine, lomustine, and carboplatin. Evidence also
supports  adequate response and tolerance of
temozolamide in the pediatric population.
Specific genetic alterations predict higher chemosensitivity
Genetic studies on LGG have shown that low grade
oligodendroglioma carrying certain genetic aberrations
responds very well to chemotherapy. These include loss of
heterozygosity of chromosome 1p and 19q.4 A n o t h e r
genetic alteration shown to make the tumor susceptible to
the alkylating action of chemotherapeutic agents is
methylation of the promoter of the methylguanine-DNA
methyltransferase (MGMT) gene.4 MGMT is a DNA repair
enzyme and hyper-methylation of its promoter restricts its
expression. There is evidence to suggest that these
genetic and epigenetic changes confer chemosensitivity in
some patients with low grade astrocytoma as well.
Perhaps genetic analysis to detect these genetic/epigenetic
changes will be used on a more routine basis in the future
to assess chemo-susceptibility of LGG subgroups. 
RADIOTHERAPY IS A VALUABLE ADJUNCT BUT OPTIMAL
TIMING IS UNKNOWN
Radiation therapy (RT) plays an adjunctive role in the
management of LGG. EORTC trials have shown that the
timing of RT (immediately after surgical resection versus
upon neuro-imaging evidence of malignant progression)
does not affect overall survival.2 0 Early institution of RT,
however, does increase progression-free survival, although
overall life expectancy does not change. Based on these
findings, it seems advisable to delay RT in all cases,
whether they have undergone tumor resection or not. The
risk of toxicity from RT, including dementia and other
encephalopathic changes, tip the risk-benefit ratio in favor
of avoiding early RT. A phase III randomized controlled trial
conducted in North America also showed that higher doses
of RT (65 Gray) actually decreased survival and increased
the incidence of radiation necrosis, when compared with
lower dose RT (50 Gray) for LGG.2 1
C O N C L U S I O N
LGG have benign histological features but possess inherent
propensity for  malignant  transformation. They are
assoc iated with seizures (which are controlled by
anticonvulsants) and sometimes headache (which may
respond to dexamethasone). Definitive treatment is based
on surgical resection (if feasible), to be followed up by RT
and possibly chemotherapy. Chemotherapy is especially
advisable in oligodendroglioma.
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Figure 7. MRI of a patient that showing a contrast-enhancing mass





• Recent change in size or contrast enhancement pattern of tumor
• Cytoreduction to diminish the chances of malignant progression
• Histopathological diagnosis
• Proximity of eloquent area of brain eloquent area
• Deep location or difficult accessibility
• Advanced age
• Poor medical condition
TABLE 7
Indications for Surgical Resection in LGG
Relative Contra-Indications
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Figure 8. Decision-making in LGG. At junctures where multiple options are available, the preferred option is marked by a thicker arrow.
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